scholarly journals Strengthened tuberculosis control programme and trend of multidrug resistant tuberculosis rate in Osaka City, Japan

2013 ◽  
Vol 4 (1) ◽  
pp. 4-10 ◽  
Author(s):  
Akira Shimouchi ◽  
Akihiro Ohkado ◽  
Kenji Matsumoto ◽  
Jun Komukai ◽  
Hideki Yoshida ◽  
...  
2018 ◽  
Vol 62 (5) ◽  
Author(s):  
Agibothu Kupparam Hemanth Kumar ◽  
Alok Kumar ◽  
Thiruvengadam Kannan ◽  
Rakesh Bhatia ◽  
Dipti Agarwal ◽  
...  

ABSTRACTWe studied the pharmacokinetics of levofloxacin (LFX), pyrazinamide (PZA), ethionamide (ETH), and cycloserine (CS) in children with multidrug-resistant tuberculosis (MDR-TB) who were being treated according to the Revised National TB Control Programme (RNTCP) guidelines in India. This observational, pharmacokinetic study was conducted in 25 children with MDR-TB at the Sarojini Naidu Medical College, Agra, India, who were being treated with a 24-month daily regimen. Serial blood samples were collected after directly observed administration of drugs. Estimations of plasma LFX, PZA, ETH, and CS were undertaken according to validated methods by high-performance liquid chromatography. Adverse events were noted at 6 months of treatment. The peak concentration (Cmax) of LFX was significantly higher in female than male children (11.5 μg/ml versus 7.3 μg/ml;P= 0.017). Children below 12 years of age had significantly higher ETH exposure (area under the concentration-time curve from 0 to 8 h [AUC0–8]) than those above 12 years of age (17.5 μg/ml · h versus 9.4 μg/ml;P= 0.030). Multiple linear regression analysis showed significant influence of gender onCmaxof ETH and age onCmaxand AUC0–8of CS. This is the first and only study from India reporting on the pharmacokinetics of LFX, ETH, PZA, and CS in children with MDR-TB treated in the Government of India program. More studies on the safety and pharmacokinetics of second-line anti-TB drugs in children with MDR-TB from different settings are required.


2017 ◽  
Vol 3 (1) ◽  
pp. 1-15
Author(s):  
Janmejaya Samal

Despite the lack of reliable information on multidrug-resistant tuberculosis (MDR-TB) epidemiology, research shows an increasing trend of MDR-TB incidence in India. Of several determinants attributable to the rising trend of MDR-TB, health systems and policy (HSP) determinants play a pivotal role. With this article, an attempt has been made to unravel the HSP challenges for the control of MDR-TB and recommend strategies to overcome that. Ten different strategies have been recommended in this article that includes operations research (OR), molecular epidemiological studies, drug susceptibility test (DST), surveillance system, advocacy communication and social mobilisation (ACSM), nutrition and livelihood support, contribution of private practitioners (PPs), human resources for health (HRH), social determinants of health and information systems. Methods of OR with the right technical expertise can help in decision-making and evaluation of the TB control programme. Molecular epidemiological studies further help identify the right strain and can help in institutionalising the right therapeutic regimen. Similarly, the DST allows extended treatment strategies, including second-line drugs. A proper surveillance system can enable the availability of the right information for public health decision-making. Communication enables and empowers the community in accessing health services and helps policymakers take informed decisions. Nutrition and livelihood support are essential in TB control as it mostly affects the poor and people in the productive age group. Further, tapping PPs is equally important as more than 50 per cent of TB patients visit them. Proper orientation of the PPs about the TB control programme is non-negotiable given these facts. The HRH issues are pertinent—staff members lack the required motivation owing to delay in payment of salaries and the lack of job promotion. The HRH form the backbone of any health system, as the mere presence of drugs, technologies and infrastructure do not suffice for the provision of healthcare. Attention on the neglected social determinants of health is required as well. Finally, all these suggestions need to be implemented in coordination with each other to bring down the scourge of MDR-TB in India.


2021 ◽  
Vol 8 (2) ◽  
pp. 16-27
Author(s):  
N.A. Pavluchenkova ◽  
A.V. Mikheeva ◽  
E.A. Sakharitova

The spread of multidrug-resistant and extensively drug-resistant tuberculosis (MDR and XDR) requires the search and implementation of not only new diagnostic methods, but also innovations in the treatment of the disease. Aim. The assessment of current treatment options for multidrug-resistant tuberculosis in different countries. Materials and Methods. There was carried out the content analysis of the official sources of 24 countries concerning the drugs that had been registered at these countries and recommended by the World Health Organization for the treatment of multidrug-resistant tuberculosis and put into circulation from 2000 to 2020: linezolid, bedaquiline, delamanid, clofazimine (as of 07.2020). The data were compared with the characteristics of the epidemiological situation in the country. Results. There was developed a six-digit classification by the following criteria: the presence of international nonproprietary names for drugs; the availability and range of dosage forms; the number of drugs subject to all dosage forms, dosages, pharmaceutical forms and units of packaging; the presence in the domestic market of the original product; the time of registration of drugs in the specified territory; the level of multi-drug resistance of the pathogen in the country per 100,000 population. Among the countries with the highest market coverage with a low (up to 0.5 per 100 thousand) level of multidrug resistance, a large share falls on European countries. As for a number of African States, there may be a threat of spreading the disease taking into account the epidemiological situation for multidrug-resistant tuberculosis and with only linezolid registered. The list of countries with a level of the same indicator above 15 per 100,000 population includes Russia and Namibia with radically different market characteristics. If Russia possesses the entire available range of medicines with the number of nomenclature items above 200, then Namibia has no more than 10 linezolid preparations registered only in tablet form. The main supplier of innovative products in the field of tuberculosis control is the Asia-Pacific region. Сonclusion. It is defined that the characteristics of the drug market differ significantly depending on the economic development of states and are determined by the indicator of the disease burden. Success in the tuberculosis control is impossible without the active development of the pharmaceutical industry and the replenishment of the market with innovative products.


Sign in / Sign up

Export Citation Format

Share Document